Reuters reported today that Bayer is looking to close a multibillion-euro acquisition deal, quoting sources who say that an announcement could be "imminent."
Piramal wasn't saying just how much it paid for the portfolio, but rather breezily claimed that the market for such Alzheimer's imaging agents could amount to $1.5 billion.
Three months of negotiations have apparently resulted in Bayer deciding that claims against its Yasmin line of birth control are worth about $220,000 each.
To make sure doctors and patients are aware of the potential dangers, the pills' labels will now include study data suggesting as much as a threefold increase in clotting risk.
Bayer failed to stop 8 women from seeking class-action status for their sex-discrimination claims against the company.
Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.
NICE has recommended the drug for stroke and embolisms in draft guidance, and final guidance may come in April.
Is intellectual property safe in India? That's the question drugmakers--and now U.S. officials--are asking.
Roche has stepped up with plans to slash the cost of Herceptin and MabThera.
The Romanian Competition Council has wrapped up an ongoing investigation into alleged antitrust practices by Bayer ($BAY), Sintofarm and 9 distributors. The result: a combined €12 million in fines the companies must pay.